Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pharmather Holdings Ltd (OP:PHRRF)

0.0423 +0.0017 (+4.19%)
Delayed Quote Updated: 3:47 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pharmather Holdings Ltd

< Previous 1 2 3 4 5 Next >
News headline image
PharmaTher Outlines Corporate Strategy and Upcoming Milestones; Launches New Corporate Website and Rebrands PERSONALIZ3D as M3DICINES
HighlightsM3DICINES™ 3D-printed medicines platform. One platform for PharmaTher's proprietary products, its network of CraftMake™ placements and partner services: CDMO, white-label... 
Via Newsfile
News headline image
PharmaTher Enters into Exclusive North American Distribution Agreement with Craft Health for CraftMake(TM) Pharmaceutical 3D Printing Platform
HighlightsPharmaTher is now the exclusive distributor in North America of Craft Health's CraftMake™ 3D printers, CraftControl™ software, CraftBlends™ printable formulations,... 
Via Newsfile
News headline image
PharmaTher Selects PD Labs, a National 503A Compounding Pharmacy, as the U.S. Center of Excellence for Its Personalized Medicine and Peptide Platform, PERSONALIZ3D(TM)
Marks the first milestone in PharmaTher's three-stage commercialization plan, advancing PERSONALIZ3D™ into early commercialization activitiesEstablishes the operating foundation to scale... 
Via Newsfile
News headline image
PharmaTher Establishes PERSONALIZ3D(TM) to Commercialize a Personalized Medicine Platform Combining Telehealth and Pharmaceutical 3D Printing
Toronto, Ontario--(Newsfile Corp. - August 11, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a... 
Via Newsfile
News headline image
PharmaTher Collaborates with Craft Health to Evaluate CraftMake(TM) GMP-Ready Pharmaceutical 3D Printing Platform for Personalized Peptides
Toronto, Ontario--(Newsfile Corp. - July 29, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a... 
Via Newsfile
Topics Artificial Intelligence
News headline image
PharmaTher Launches Personaliz3D Peptides(TM) to Advance Personalized Peptide Care Following Positive FDA Advisory Committee Recommendations
New division will address the limitations of traditional peptide compounding through 3D printing and AIPharmaTher plans to connect patients, physicians... 
Via Newsfile
Topics Artificial Intelligence
News headline image
PharmaTher Enters into Collaboration Agreement for KetaMist(R) to Advance Needle-Free Ketamine Treatment Toward FDA Approval
Collaboration combines more than 9,000 KetaMist® patient treatments with PharmaTher's prior FDA-approved ketamine experiencePursuing an efficient FDA development pathway toward... 
Via Newsfile
News headline image
PharmaTher Updates Strategy on Personalized Medicines for Peptides and Psychedelics
Toronto, Ontario--(Newsfile Corp. - July 15, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a... 
Via Newsfile
Topics Artificial Intelligence
News headline image
PharmaTher Evolves Platform Strategy with MEDBOTX(TM) Robotic 3D Printing for Personalized Medicines
MEDBOTX™ represents the evolution into a broader point-of-care manufacturing platform designed for personalized medicines, peptides and advanced dose formatsPotential U.S.... 
Via Newsfile
News headline image
PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus
Toronto, Ontario--(Newsfile Corp. - May 13, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) ("PharmaTher" or the "Company"), a... 
Via Newsfile
News headline image
PharmaTher Highlights Strategic Ketamine Opportunity Following New U.S. Executive Order on Psychedelic Treatments for Serious Mental Illness
Company believes supportive U.S. policy momentum may strengthen the strategic value of its ketamine patch, KetaVault™ platform, retained ketamine programs,... 
Via Newsfile
News headline image
PharmaTher's Microneedle Patch Platforms Positioned to Benefit from Major U.S. Catalysts in Psychedelics and Peptides
U.S. regulatory momentum in psychedelics and peptides could open new commercial opportunities for PharmaTher's PatchPrint™ automated manufacturing platform and PharmaPatch™... 
Via Newsfile
Topics Government Intellectual Property
News headline image
PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery
Anticipated peptide reclassification could expand the addressable market for PharmaTher's PharmaPatch™ product strategy and PatchPrint™ manufacturing platform, strengthening its position... 
Via Newsfile
News headline image
PharmaTher Announces Filing of U.S. Patent Application for its Peptide Microneedle Patch Technology
Patent filing intended to strengthen PharmaTher's peptide formulation capabilities for PharmaPatch™ while complementing PatchPrint™ as part of the Company's broader... 
Via Newsfile
Topics Intellectual Property
News headline image
PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches
Leveraging its PharmaPatch™ experience, the Company is introducing PatchPrint™ to support existing microneedle patch programs and expand into on-demand personalized... 
Via Newsfile
Topics Intellectual Property
News headline image
PharmaTher Expands PharmaPatch Delivery Platform into Therapeutic Peptides for the U.S. Market
Toronto, Ontario--(Newsfile Corp. - March 3, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical... 
Via Newsfile
News headline image
PharmaTher Launches Strategic Initiative to Pursue Health Canada Approval for Generic Semaglutide in Canada, Building on FDA-Approved Ketamine Success
Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - PharmaTher Holdings Ltd. (CSE: PHRM) (OTCQB: PHRRF) (the "Company" or "PharmaTher"), a... 
Via Newsfile
Topics Supply Chain
News headline image
PharmaTher Expands PharmaPatch(TM) Platform into GLP-1 for Obesity, Leveraging Its Ketamine and Psychedelic Patch Programs
Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty pharmaceutical... 
Via Newsfile
News headline image
PharmaTher CEO Publishes Letter to Shareholders
Toronto, Ontario--(Newsfile Corp. - January 2, 2026) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher") today announced that... 
Via Newsfile
News headline image
PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise
Toronto, Ontario--(Newsfile Corp. - December 2, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a... 
Via Newsfile
News headline image
PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program
Toronto, Ontario--(Newsfile Corp. - November 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life... 
Via Newsfile
News headline image
PharmaTher Applauds FDA's Commissioner's National Priority Voucher (CNPV) Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505(b)(2) Focus, and Upside from Strategic ANDA Sale
Toronto, Ontario--(Newsfile Corp. - October 17, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a... 
Via Newsfile
News headline image
PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease
Toronto, Ontario--(Newsfile Corp. - October 16, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life... 
Via Newsfile
Topics Intellectual Property
News headline image
PharmaTher Announces KetAImine(TM) - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505(b)(2) NDA Filings
Toronto, Ontario--(Newsfile Corp. - October 15, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty life... 
Via Newsfile
Topics Artificial Intelligence
News headline image
PharmaTher Provides Update on Ketamine Program for LID-Parkinson's Disease
Phase 3 program targeting a potential US$2.2B U.S. market opportunity505(b)(2) regulatory path leveraging prior human data to reduce risk, cost,... 
Via Newsfile
Topics Intellectual Property
News headline image
PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy
From PharmaTher Holdings Ltd.
Via GlobeNewswire
News headline image
PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate over US$25 Million in Milestone and Profit-Sharing Payments
Toronto, Ontario--(Newsfile Corp. - October 1, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a... 
Via Newsfile
News headline image
PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments
From PharmaTher Holdings Ltd.
Via GlobeNewswire
News headline image
PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine (KETARx(TM)), Aligned with FDA's CNPV National Priority Initiative
Toronto, Ontario--(Newsfile Corp. - August 27, 2025) - PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) (the "Company" or "PharmaTher"), a specialty... 
Via Newsfile
Topics Death
News headline image
PharmaTher Provides Corporate Update Following FDA Approval of Ketamine (KETARx™)
Company advancing U.S. commercialization with FDA-approved ketamine and rare disorder NDA filings 
From PharmaTher Holdings Ltd.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.